HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer

NCT04676477 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

246

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer (NSCLC)

Interventions

DRUG: HER3-DXd
DRUG: HER3-DXd
DRUG: Osimertinib
DRUG: Osimertinib
DRUG: HER3-DXd
DRUG: HER3-DXd
DRUG: Osimertinib

Sponsor

Daiichi Sankyo

Collaborators

[object Object]
[object Object]